HARBIN, China, Sept. 15 /PRNewswire-Asia/ -- Renhuang Pharmaceuticals, Inc. (NYSE Amex: CBP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products,
bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that it has cancelled its earnings conference call previously scheduled for 9.00 a.m. EDT on September 16, 2010. The Company will reschedule the conference call for a later date and will announce this information in a press release. The Company has also filed a Form 12b-25 with the Securities and Exchange Commission as information necessary for the filing of a complete and accurate report on Form 10-Q could not be gathered within the prescribed time period.
About Renhuang Pharmaceuticals, Inc.
Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three
GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. Company Website: http://www.renhuang.com .
For more information, please contact:
Renhuang Pharmaceuticals, Inc.
Ms. Portia Tan, IR Contact
Phone: +86-451-8260-2162
Email: ir@renhuang.com
CCG Investor Relations:
Mr. Mark Collinson, Partner
Phone: +1-310-954-1343 (Los Angeles)
Email: mark.collinson@ccgir.com
Mr. Crocker Coulson, President
Phone: +1-646-213-1915 (New York)
Email: crocker.coulson@ccgir.com
